We know clinical supply

Every clinical supply programme we run is led by a dedicated project manager — an experienced clinical supply specialist who takes the time to understand your study design, your supply chain constraints, and your organisation before the first packaging run begins.

Our project managers are your single point of contact across all supply activities — comparator sourcing, packaging, labelling, logistics, and returns. They work in close collaboration with our operations teams and are recognised for fast, proactive response times that keep your programme moving.

What this means in practice:

• In-depth knowledge of your business, protocol, and supply chain built from day one
• All decisions made within the context of your distribution strategy, not in isolation
• Proactive identification of packaging and supply challenges before they become timeline risks
• A single escalation point across all clinical supply activities

In a blinded clinical trial, the placebo is not a secondary deliverable — it is a critical component of the study design. A placebo that differs from the active product in colour, size, weight, or dissolution profile introduces observable differences that can unblind investigators or patients and compromise the validity of clinical data.

We develop and manufacture placebos that match the active product in appearance, physical characteristics, and primary packaging presentation — ensuring that no observable difference exists between active and placebo arms of your study.

Placebo manufacturing capabilities:

• Analytical services including release testing and stability studies
• Capsules and tablets across multiple formulation types
• Colour and size matched to active product strength
• Primary packaging identical to the active product
• Batch sizes from 200 to 80,000 units — scaled to clinical phase requirements

Traditional clinical labelling — where labels are printed and applied well in advance of shipment — creates inflexibility that costs time and generates waste. Country mix changes, protocol amendments, recruitment dynamic shifts, and expiry date extensions all require label updates that, in a conventional workflow, mean repackaging, waste disposal, and delay.

Our Just-in-Time (JIT) labelling approach decouples packaging from label application, keeping labels unprinted until close to the point of shipment. This delivers meaningful operational advantages for studies at any phase:

• Shorter lead times from packaging to site receipt of patient kits
• Reduced material waste — no pre-printed labels rendered obsolete by protocol or country changes
• Flexible country and language management — adapt to recruitment realities without repackaging
• Elimination of complex multi-language booklet labels in many scenarios
• Re-labelling and over-labelling for expiry date updates on already-packaged materials

We provide GMP-compliant storage and global distribution for clinical trial materials, with full inventory and expiry visibility and the operational agility to respond to the unpredictable realities of clinical trial execution.

Storage:

• Controlled ambient (15–25°C) and refrigerated (2–8°C) conditions
• Continuous temperature monitoring and deviation management

Distribution:

• Temperature-controlled distribution to clinical sites within the EU and for global export
• Door-to-door delivery of IMP to clinical sites and depots
• On-demand shipment capability with a target lead time of one week
• Inventory management and expiry tracking to prevent supply interruptions

Sampling kit design sits at the interface of clinical supply and bioanalytical science — and when these two functions are not aligned, the result is handling errors, protocol deviations, and compromised sample data.

We design and supply sampling kits and ancillary study materials in direct coordination with our bioanalytical capabilities — ensuring that kit design, sample handling instructions, storage conditions, and chain-of-custody documentation are aligned with the analytical methods processing the samples.

• Consistent sampling kits across all clinical sites
• Design aligned with bioanalytical workflows from the outset
• Combined shipment of IMP and sampling materials where operationally appropriate
• Simplified site-level procedures to reduce investigator burden and protocol deviations